Skip to main content
Top
Published in: Cancer Microenvironment 1/2010

Open Access 01-12-2010 | Original Paper

Mammographic Density and Matrix Metalloproteinases in Breast Tissue

Authors: Jana S. Steude, Gertraud Maskarinec, Eva Erber, Martijn Verheus, Brenda Y. Hernandez, Jeffrey Killeen, J. Mark Cline

Published in: Cancer Microenvironment | Issue 1/2010

Login to get access

Abstract

Mammographic density is a strong risk factor for breast cancer, yet the underlying histopathologic correlates are not clear. Matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) play important roles in multiple stages of tumorigenesis. This study examined the association between mammographic density and expression of MMPs 1, 3, 9, and 12 and TIMP3 in benign and malignant breast tissue of 277 women with mainly Caucasian and Japanese ancestry. Tissue microarrays with up to 4 benign and 4 malignant cores per woman were stained immunohistochemically and evaluated. Digitized prediagnostic mammograms were assessed for densities using a computer-assisted method. General linear models adjusted for known confounders were applied to estimate mean densities by staining category. Strong expression of all MMPs was about twice as frequent in malignant as in benign tissue, while TIMP3 expression in stromal tissue was higher in benign than malignant cores. For MMP3 and 9, less than 10% of cores stained positive; thus, they were not further analyzed. None of the markers showed a statistically significant association with breast density in the entire study population and ethnic-specific results were conflicting and difficult to explain. Although not statistically significant, mean density was consistently lower with more extensive TIMP3 expression in stromal and epithelial tissue. These findings indicate that the higher breast cancer risk in women with dense breasts may be influenced by lower TIMP3 expression. However, future investigations into activities and ratios of additional proteases and their inhibitors as well as other pathways, such as inflammation, are needed.
Literature
1.
go back to reference McCormack VA, dos Santos Silva I (2006) Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15:1159–1169CrossRefPubMed McCormack VA, dos Santos Silva I (2006) Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15:1159–1169CrossRefPubMed
3.
go back to reference Alowami S, Troup S, Al-Haddad S et al (2003) Mammographic density is related to stroma and stromal proteoglycan expression. Breast Cancer Res 5:R129–R135CrossRefPubMed Alowami S, Troup S, Al-Haddad S et al (2003) Mammographic density is related to stroma and stromal proteoglycan expression. Breast Cancer Res 5:R129–R135CrossRefPubMed
4.
go back to reference Boyd NF, Rommens JM, Vogt K et al (2005) Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 6:798–808CrossRefPubMed Boyd NF, Rommens JM, Vogt K et al (2005) Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 6:798–808CrossRefPubMed
5.
go back to reference Warren R, Lakhani SR (2003) Can the stroma provide the clue to the cellular basis for mammographic density? Breast Cancer Res 5:225–227CrossRefPubMed Warren R, Lakhani SR (2003) Can the stroma provide the clue to the cellular basis for mammographic density? Breast Cancer Res 5:225–227CrossRefPubMed
6.
go back to reference Bartow SA, Pathak DR, Mettler FA (1990) Radiographic microcalcification and parenchymal pattern as indicators of histologic “high-risk” benign breast disease. Cancer 66:1721–1725CrossRefPubMed Bartow SA, Pathak DR, Mettler FA (1990) Radiographic microcalcification and parenchymal pattern as indicators of histologic “high-risk” benign breast disease. Cancer 66:1721–1725CrossRefPubMed
7.
go back to reference Urbanski S, Jensen HM, Cooke G et al (1988) The association of histological and radiological indicators of breast cancer risk. Br J Cancer 58:474–479PubMedCrossRef Urbanski S, Jensen HM, Cooke G et al (1988) The association of histological and radiological indicators of breast cancer risk. Br J Cancer 58:474–479PubMedCrossRef
8.
go back to reference Ghajar CM, Bissell MJ (2008) Extracellular matrix control of mammary gland morphogenesis and tumorigenesis: insights from imaging. Histochem Cell Biol 130:1105–1118CrossRefPubMed Ghajar CM, Bissell MJ (2008) Extracellular matrix control of mammary gland morphogenesis and tumorigenesis: insights from imaging. Histochem Cell Biol 130:1105–1118CrossRefPubMed
9.
go back to reference Koshiba T, Hosotani R, Wada M et al (1998) Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer 82:642–650CrossRefPubMed Koshiba T, Hosotani R, Wada M et al (1998) Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer 82:642–650CrossRefPubMed
10.
go back to reference Coussens LM, Tinkle CL, Hanahan D et al (2000) MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103:481–490CrossRefPubMed Coussens LM, Tinkle CL, Hanahan D et al (2000) MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103:481–490CrossRefPubMed
11.
go back to reference Baker AH, George SJ, Zaltsman AB et al (1999) Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer 79:1347–1355CrossRefPubMed Baker AH, George SJ, Zaltsman AB et al (1999) Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer 79:1347–1355CrossRefPubMed
12.
go back to reference Guo YP, Martin LJ, Hanna W et al (2001) Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol Biomarkers Prev 10:243–248PubMed Guo YP, Martin LJ, Hanna W et al (2001) Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol Biomarkers Prev 10:243–248PubMed
13.
go back to reference Maskarinec G, Pagano I, Lurie G et al (2005) Mammographic density and breast cancer risk: the multiethnic cohort. Am J Epidemiol 162:743–752CrossRefPubMed Maskarinec G, Pagano I, Lurie G et al (2005) Mammographic density and breast cancer risk: the multiethnic cohort. Am J Epidemiol 162:743–752CrossRefPubMed
14.
go back to reference Kolonel LN, Henderson BE, Hankin JH et al (2000) A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol 151:346–357PubMed Kolonel LN, Henderson BE, Hankin JH et al (2000) A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol 151:346–357PubMed
15.
go back to reference Verheus M, Maskarinec G, Erber E et al (2009) Mammographic density and epithelial histopathologic markers. BMC Cancer 9:182CrossRefPubMed Verheus M, Maskarinec G, Erber E et al (2009) Mammographic density and epithelial histopathologic markers. BMC Cancer 9:182CrossRefPubMed
16.
go back to reference Maskarinec G, Erber E, Verheus M et al (2009) Soy consumption and histopathologic markers in breast tissue using tissue microarrays. Nutr Cancer 61(5):708–716 Maskarinec G, Erber E, Verheus M et al (2009) Soy consumption and histopathologic markers in breast tissue using tissue microarrays. Nutr Cancer 61(5):708–716
17.
go back to reference Byng JW, Boyd NF, Fishell E et al (1994) The quantitative analysis of mammographic densities. Phys Med Biol 39:1629–1638CrossRefPubMed Byng JW, Boyd NF, Fishell E et al (1994) The quantitative analysis of mammographic densities. Phys Med Biol 39:1629–1638CrossRefPubMed
18.
go back to reference Stone J, Gunasekara A, Martin LJ et al (2003) The detection of change in mammographic density. Cancer Epidemiol Biomarkers Prev 12:625–630PubMed Stone J, Gunasekara A, Martin LJ et al (2003) The detection of change in mammographic density. Cancer Epidemiol Biomarkers Prev 12:625–630PubMed
19.
go back to reference Goodman MT, Hernandez BY, Hewitt S et al (2005) Tissues from population-based cancer registries: a novel approach to increasing research potential. Hum Pathol 36:812–820CrossRefPubMed Goodman MT, Hernandez BY, Hewitt S et al (2005) Tissues from population-based cancer registries: a novel approach to increasing research potential. Hum Pathol 36:812–820CrossRefPubMed
20.
go back to reference Anderson WF, Luo S, Chatterjee N et al (2008) Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue respository of the Surveillance, Epidemiology, and End Results (SEER) program. Breast Cancer Res Treat 113(1):189–196 Anderson WF, Luo S, Chatterjee N et al (2008) Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue respository of the Surveillance, Epidemiology, and End Results (SEER) program. Breast Cancer Res Treat 113(1):189–196
21.
go back to reference Shi SR, Key ME, Kalra KL (1991) Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39:741–748PubMed Shi SR, Key ME, Kalra KL (1991) Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39:741–748PubMed
22.
go back to reference Wellings SR, Wolfe JN (1978) Correlative studies of the histological and radiographic appearance of the breast parenchyma. Radiology 129:299–306PubMed Wellings SR, Wolfe JN (1978) Correlative studies of the histological and radiographic appearance of the breast parenchyma. Radiology 129:299–306PubMed
23.
go back to reference Bright RA, Morrison AS, Brisson J et al (1988) Relationship between mammographic and histologic features of breast tissue in women with benign biopsies. Cancer 61:266–271CrossRefPubMed Bright RA, Morrison AS, Brisson J et al (1988) Relationship between mammographic and histologic features of breast tissue in women with benign biopsies. Cancer 61:266–271CrossRefPubMed
24.
go back to reference Coussens LM, Werb Z (1996) Matrix metalloproteinases and the development of cancer. Chem Biol 3:895–904CrossRefPubMed Coussens LM, Werb Z (1996) Matrix metalloproteinases and the development of cancer. Chem Biol 3:895–904CrossRefPubMed
25.
go back to reference Nelson AR, Fingleton B, Rothenberg ML et al (2000) Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18:1135–1149PubMed Nelson AR, Fingleton B, Rothenberg ML et al (2000) Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18:1135–1149PubMed
26.
go back to reference Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161–174CrossRefPubMed Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161–174CrossRefPubMed
27.
go back to reference Wang M, Liu YE, Greene J et al (1997) Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. Oncogene 14:2767–2774CrossRefPubMed Wang M, Liu YE, Greene J et al (1997) Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. Oncogene 14:2767–2774CrossRefPubMed
28.
go back to reference Khokha R, Denhardt DT (1989) Matrix metalloproteinases and tissue inhibitor of metalloproteinases: a review of their role in tumorigenesis and tissue invasion. Invasion Metastasis 9:391–405PubMed Khokha R, Denhardt DT (1989) Matrix metalloproteinases and tissue inhibitor of metalloproteinases: a review of their role in tumorigenesis and tissue invasion. Invasion Metastasis 9:391–405PubMed
29.
go back to reference Albini A, Melchiori A, Santi L et al (1991) Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst 83:775–779CrossRefPubMed Albini A, Melchiori A, Santi L et al (1991) Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst 83:775–779CrossRefPubMed
30.
go back to reference Valente P, Fassina G, Melchiori A et al (1998) TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer 75:246–253CrossRefPubMed Valente P, Fassina G, Melchiori A et al (1998) TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer 75:246–253CrossRefPubMed
31.
go back to reference Ahonen M, Baker AH, Kahari VM (1998) Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res 58:2310–2315PubMed Ahonen M, Baker AH, Kahari VM (1998) Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res 58:2310–2315PubMed
32.
go back to reference Anand-Apte B, Bao L, Smith R et al (1996) A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth. Biochem Cell Biol 74:853–862CrossRefPubMed Anand-Apte B, Bao L, Smith R et al (1996) A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth. Biochem Cell Biol 74:853–862CrossRefPubMed
33.
go back to reference Sternlicht MD, Bissell MJ, Werb Z (2000) The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter. Oncogene 19:1102–1113CrossRefPubMed Sternlicht MD, Bissell MJ, Werb Z (2000) The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter. Oncogene 19:1102–1113CrossRefPubMed
34.
go back to reference Balduyck M, Zerimech F, Gouyer V et al (2000) Specific expression of matrix metalloproteinases 1, 3, 9 and 13 associated with invasiveness of breast cancer cells in vitro. Clin Exp Metastasis 18:171–178CrossRefPubMed Balduyck M, Zerimech F, Gouyer V et al (2000) Specific expression of matrix metalloproteinases 1, 3, 9 and 13 associated with invasiveness of breast cancer cells in vitro. Clin Exp Metastasis 18:171–178CrossRefPubMed
35.
go back to reference Hernandez BY, Frierson HF, Moskaluk CA et al (2005) CK20 and CK7 protein expression in colorectal cancer: demonstration of the utility of a population-based tissue microarray. Hum Pathol 36:275–281CrossRefPubMed Hernandez BY, Frierson HF, Moskaluk CA et al (2005) CK20 and CK7 protein expression in colorectal cancer: demonstration of the utility of a population-based tissue microarray. Hum Pathol 36:275–281CrossRefPubMed
36.
go back to reference Yang XR, Charette LA, Garcia-Closas M et al (2006) Construction and validation of tissue microarrays of ductal carcinoma in situ and terminal duct lobular units associated with invasive breast carcinoma. Diagn Mol Pathol 15:157–161CrossRefPubMed Yang XR, Charette LA, Garcia-Closas M et al (2006) Construction and validation of tissue microarrays of ductal carcinoma in situ and terminal duct lobular units associated with invasive breast carcinoma. Diagn Mol Pathol 15:157–161CrossRefPubMed
37.
go back to reference Hojilla CV, Wood GA, Khokha R (2008) Inflammation and breast cancer: metalloproteinases as common effectors of inflammation and extracellular matrix breakdown in breast cancer. Breast Cancer Res 10:205CrossRefPubMed Hojilla CV, Wood GA, Khokha R (2008) Inflammation and breast cancer: metalloproteinases as common effectors of inflammation and extracellular matrix breakdown in breast cancer. Breast Cancer Res 10:205CrossRefPubMed
Metadata
Title
Mammographic Density and Matrix Metalloproteinases in Breast Tissue
Authors
Jana S. Steude
Gertraud Maskarinec
Eva Erber
Martijn Verheus
Brenda Y. Hernandez
Jeffrey Killeen
J. Mark Cline
Publication date
01-12-2010
Publisher
Springer Netherlands
Published in
Cancer Microenvironment / Issue 1/2010
Print ISSN: 1875-2292
Electronic ISSN: 1875-2284
DOI
https://doi.org/10.1007/s12307-009-0031-x

Other articles of this Issue 1/2010

Cancer Microenvironment 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine